Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Net Income
Bottom-line profit after all expenses, interest, and taxes.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$23.52M, compared with -$20.31M a year earlier. Trailing-twelve-month net income was -$87.07M.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$68.08M (+18.8%) for the fiscal year ending Dec 2026, a step up from the -43.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.52M-13.2% QoQ
- Last fiscal yearDec 2025
- -$83.87M-43.4% YoY
- LTMMar 2026
- -$87.07M-34.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.8% | -15.9% | -0.1 pp |
| 1 year | -43.4% | +18.8% | +62.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (83.87M) USD
- Year-over-year change
- -43.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (83.87M) | -43.4% |
| FY2024 | 2024-12-31 | (58.49M) | -111.2% |
| FY2023 | 2023-12-31 | (27.7M) | +52.6% |
| FY2022 | 2022-12-31 | (58.39M) | +18.7% |
| FY2021 | 2021-12-31 | (71.83M) | — |
Net Income vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -34.3% is the 7th highest of 9, against a peer median of +16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -€42.91M EUR | +4.0% | — | 146303.9% | |
| LTM Mar 2026 | -$44.49M USD | -102.3% | — | 98.7% | |
| LTM Mar 2026 | -$49.87M USD | +29.4% | — | 4987.4% | |
| FY2025 | -$55.48M USD | -255.0% | — | 86687.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$87.07M USD | -34.3% | — | — |
| LTM Mar 2026 | -$88.87M USD | +31.7% | — | — | |
| LTM Mar 2026 | -$108M USD | -21.2% | — | — | |
| LTM Mar 2026 | -$124.13M USD | +44.6% | — | — | |
| LTM Mar 2026 | -$153.6M USD | +37.4% | — | 154.2% | |
| Peer median (excluding ARTV) | — | +16.7% | — | 4987.4% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2M | 4.93M | 33.49M | 251K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 2M | 4.93M | 33.49M | 251K | (2.6M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 42.41M | 43.98M | 50.25M | 50.33M | 69.54M |
| Selling, General & Admin | 12.86M | 20.78M | 13.91M | 17.21M | 20.27M |
| Operating Expenses | 55.27M | 64.76M | 64.16M | 67.53M | 88.01M |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| EBITDA | (71.58M) | (57.18M) | (25.36M) | (56.06M) | (81.27M) |
| EBITDA Margin | -3575.3% | -1159.5% | -75.7% | -22335.5% | — |
| Operating Income | (53.27M) | (59.83M) | (30.67M) | (67.28M) | (90.61M) |
| Operating Margin | -2660.9% | -1213.3% | -91.6% | -26805.6% | — |
| Interest Income | 0 | 1.29M | 2.54M | 5.35M | 5.96M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (18.55M) | 1.49M | 3.05M | 8.79M | 6.75M |
| Income Before Tax | (71.83M) | (58.34M) | (27.62M) | (58.49M) | (83.87M) |
| Pre-Tax Margin | -3587.7% | -1183.0% | -82.5% | -23304.0% | — |
| Income Tax Expense | 0 | 53K | 72K | 0 | 0 |
| Net Income | (71.83M) | (58.39M) | (27.7M) | (58.49M) | (83.87M) |
| Net Margin | -3587.7% | -1184.1% | -82.7% | -23304.0% | — |
| EPS (Basic) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| EPS (Diluted) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| Weighted Avg Shares | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
| Weighted Avg Shares (Diluted) | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.